Article
A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.
Cancer - 1 Aug 1993
Hayashi Y, Hoon D S, Foshag L J, Park M S, Terasaki P I, Morton D L
Abstract excerpt
BACKGROUND: The authors have demonstrated that immunization with melanoma whole-cell vaccine (MCV) augments T-cell responses to melanoma and that cytotoxic T-cells (CTL) recognize allogeneic melanoma-bearing shared HLA-A antigens. A preclinical model was developed to assess CTL activation in vitro using melanoma lines as stimulators. HLA-A2 expression is predominant in melanoma patients and plays a role in HLA...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.